India’s First Phase 3 Dengue Vaccine Trial Hits 50% Enrolment Mark

India's First Phase 3 Dengue Vaccine Trial has reached a crucial milestone by achieving a 50% enrolment mark with its indigenous vaccine, DengiAll. This development is significant for UPSC aspirants, especially for those focusing on GS Paper 3, which covers Science & Technology. Last Updated: 2025-07-03

Key Facts About India's First Phase 3 Dengue Vaccine Trial

• Vaccine Name: DengiAll
• Developer: Panacea Biotec in collaboration with NIH
• Enrolment: Over 7,000 participants enrolled
• Target: All four dengue virus subtypes: DEN-1, DEN-2, DEN-3, DEN-4
• Safety: No major safety issues reported
• Current Cases in India: Over 230,000 reported cases
• Deaths: 297 reported deaths due to dengue
• Trial Sites: 20 locations across India
• Age Range: Participants aged 18-60
• Follow-up Duration: Two years after vaccination
• Principal Investigator: Dr. Suchit Kamble
• Trial Coordination: ICMR-NITVAR
• Expected Completion: Last quarter of 2027
• Initial Findings: Indicate no safety concerns
• Importance: Critical for preventing severe dengue manifestations

India's Health Security and Vaccine Development

The Phase 3 trial of the DengiAll vaccine is a pivotal step in bolstering India's health security and self-reliance in vaccine development. Dengue fever poses a significant public health challenge, with India reporting over 230,000 cases and 297 deaths in recent times. The successful development of DengiAll could position India as a leader in dengue prevention, contributing to global health security and aligning with India's strategic goals of enhancing healthcare infrastructure and innovation.

Related Government Schemes/Policies

• National Vector Borne Disease Control Programme (NVBDCP): Aims to control vector-borne diseases including dengue.
• Make in India: Encourages indigenous production and innovation in healthcare.
• Ayushman Bharat: Focuses on providing comprehensive healthcare services.

UPSC Relevance

• GS Paper 3: Science & Technology - Developments and their applications and effects in everyday life.
• Prelims Angle: Questions on the vaccine name, developer, and target virus subtypes.
• Mains Angle: Analytical themes on India's healthcare innovation and public health strategies.
• Essay Paper: Topics on public health challenges and innovations in India.

FAQ Section

• What is DengiAll? DengiAll is an indigenous tetravalent dengue vaccine developed by Panacea Biotec in collaboration with the NIH, targeting all four dengue virus subtypes.
• Why is the DengiAll trial important? The trial is crucial as it aims to provide a comprehensive solution to dengue, a significant public health issue in India, with over 230,000 cases reported.
• What are the key features of the DengiAll trial? The trial involves over 7,000 participants across 20 locations in India, with a follow-up duration of two years post-vaccination to ensure safety and efficacy.